Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective To assess the association between ACEI/ARB use and mortality in CKD patients. Background There is insufficient evidence about the association of angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) with mortality in chronic kidney disease (CKD) patients. Methods A logistic regression analysis was used to calculate the propensity of ACEI/ARB initiation in 141,413 US veterans with non-dialysis CKD previously unexposed to ACEI/ARB treatment. We examined the association of ACEI/ARB administration with all-cause mortality in patients matched by propensity scores, using the Kaplan-Meier method and Cox models in “intention-to-treat” analyses, and in generalized linear models with binary outcomes and inverse probability treatment weighing (IPTW) in “as-treated” analyses. Results The mean±SD age of the patients at baseline was 75±10 years, 8% of patients were black, and 22% were diabetic. ACEI/ARB administration was associated with significantly lower risk of mortality both in the intention-to-treat analysis (HR=0.81; 95%CI: 0.78-0.84, p<0.001) and in the as-treated analysis with IPTW (OR=0.37; 95%CI: 0.34-0.41, p<0.001). The association of ACEI/ARB treatment with lower risk of mortality was present in all examined subgroups. Conclusions In this large contemporary cohort of non-dialysis dependent CKD patients, ACEI/ARB administration was associated with greater survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452 · cited 1×
“6 using the Deyo-modification for administrative datas ets, without including kidney disease.(35,36) Data on select laboratory variables were collected from October 1, 2004 through September 30, 2009 using the DSS National Data Extracts Laboratory Results file.”
Method(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 2×
“336 Charlson Comorbidity Index (median; IQR) 3; (2-5) 3; (2-5) <0.”
BackgroundThe SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 5×
“Clinical trials of ACEI and/or ARB that included CKD patients with more advanced stages examined primarily renal and composite renal outcomes (which sometimes included mortality), but not mortality alone.(6-9,12,25) An earlier meta-analysis of smaller RCTs examining primarily the effect of ACEI on progression of non-d…”
BackgroundInfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910 · cited 1×
“stage (stages 1-3) CKD(22) identified only 3 studies(10,23,24) and concluded that the evidence was insufficient to determine whether ACEI or ARB is beneficial in this population.”
BackgroundEfficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710 · cited 2×
“Clinical trials of ACEI and/or ARB that included CKD patients with more advanced stages examined primarily renal and composite renal outcomes (which sometimes included mortality), but not mortality alone.(6-9,12,25) An earlier meta-analysis of smaller RCTs examining primarily the effect of ACEI on progression of non-d…”
Rahman, M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.936 · Cited by 340 · cited 3×
“Given the high mortality rates observed in patients with non-dialysis dependent CKD, the paucity of interventions available to lower these mortality rates, and the difficulties associated with conducting properly powered randomized controlled trials in this population, our results could have important clinical and pub…”
Background
Cited by
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Grams, M. E., Sang, Y., Coresh, J., Ballew, S., Matsushita, K., Molnar, M. Z., Szabo, Z., Kalantar-Zadeh, K., & Kovesdy, C. P. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.07.022 · Cited by 348
Self-citationWriting Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 213
Rosano, G. M. C., Tamargo, J., Kjeldsen, K. P., Lainscak, M., Agewall, S., Anker, S. D., Ceconi, C., Coats, A. J. S., Drexel, H., Filippatos, G., et al. (2018) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvy015 · Cited by 204
Qiao, Y., Shin, J.-I., Chen, T. K., Inker, L. A., Coresh, J., Alexander, G. C., Jackson, J. W., Chang, A. R., & Grams, M. E. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.0193 · Cited by 199
Molnar, M. Z., Alhourani, H. M., Wall, B. M., Lu, J. L., Streja, E., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2015) · Hepatology · doi:10.1002/hep.27664 · Cited by 161
Self-citationNovak, M., Mucsi, I., Rhee, C. M., Streja, E., Lu, J. L., Kalantar-Zadeh, K., Molnar, M. Z., & Kovesdy, C. P. (2016) · Diabetes Care · doi:10.2337/dc16-0048 · Cited by 104
Self-citationMicrobiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD
Briskey, D., Tucker, P. S., Johnson, D. W., & Coombes, J. S. (2016) · Nitric Oxide · doi:10.1016/j.niox.2016.05.002 · Cited by 47
Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy
Sampani, E., Theodorakopoulou, M., Iatridi, F., & Sarafidis, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2245756 · Cited by 11
Metadata
- Authors
- Molnar, M. Z., Kalantar-Zadeh, K., Lott, E. H., Lu, J. L., Malakauskas, S. M., Ma, J. Z., Quarles, D. L., & Kovesdy, C. P.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 63
- Issue
- 7
- Pages
- 650-658
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2041725636
- Cited by
- 163
- References
- 12
- FWCI
- 12.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.